Previous Article | Next Article 
Journal of Virology, August 2001, p. 7161-7174, Vol. 75, No. 15
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.15.7161-7174.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Transcription Pattern of Human Herpesvirus 8 Open Reading Frame
K3 in Primary Effusion Lymphoma and Kaposi's Sarcoma
Paola
Rimessi,1
Angela
Bonaccorsi,1
Michael
Stürzl,2
Marina
Fabris,1
Egidio
Brocca-Cofano,1
Antonella
Caputo,1
Gianna
Melucci-Vigo,3
Mario
Falchi,4
Aurelio
Cafaro,3
Enzo
Cassai,1
Barbara
Ensoli,3,* and
Paolo
Monini3
Section of Microbiology, Department of Diagnostic and
Experimental Medicine, University of Ferrara, 44100 Ferrara,1 and Laboratories of
Virology3 and
Ultrastructure,4 Istituto Superiore di
Sanità, 00161 Rome, Italy, and Institute of Molecular
Virology, GSF-National Research Center for Environment and Health,
85764 Neuherberg, Germany2
Received 30 January 2001/Accepted 30 April 2001
 |
ABSTRACT |
Human herpesvirus 8 (HHV-8) is found in immunoblastic B cells of
patients with multicentric Castleman's disease (MCD) and, predominantly in a latent form, in primary effusion lymphoma
(PEL) cells and Kaposi's sarcoma (KS) spindle cells. Recent
studies have shown that upon reactivation, HHV-8 expresses factors
that downregulate major histocompatibility class I
proteins and coactivation molecules and that may enable
productively infected cells to escape cytotoxic T lymphocytes and
natural killer cell responses. One of these viral factors is
encoded by open reading frame (ORF) K3. Here we show that in PEL
cells, ORF K3 is expressed through viral transcripts that are
induced very early upon virus reactivation, including bicistronic RNA
molecules containing coding sequences from viral ORFs K3 and 70. Specifically, we found that a bicistronic transcript was expressed in
the absence of de novo protein synthesis, thereby identifying a novel
HHV-8 immediate-early gene product. Several features of the RNA
molecules encoding the K3 product, including multiple transcriptional
start sites, multiple donor splicing sites, and potential alternative
ATG usage, suggest that there exists a finely tuned modulation of ORF
K3 expression. By contrast, ORF K3 transcripts are not detected in the
majority of cells present in KS lesions that are latently infected by
the virus, suggesting that there are other, as-yet-unknown
mechanisms of immune evasion for infected KS spindle cells.
Nevertheless, because HHV-8 viremia precedes the development
of KS lesions and is associated with the recrudescence of MCD symptoms,
the prompt expression of ORF K3 in productively infected circulating
cells may be important for virus pathogenesis. Thus, molecules
targeting host or viral factors that activate ORF K3 expression or
inactivate the biological functions of the K3 product should be
exploited for the prevention or treatment of HHV-8-associated diseases
in at-risk individuals.
 |
INTRODUCTION |
Human herpesvirus 8 (HHV-8)
(8) is a novel gammaherpesvirus found in immunoblastic B
cells from persons with multicentric Castleman's disease (MCD),
primary effusion lymphoma (PEL) cells, and Kaposi's sarcoma (KS)
spindle cells or endothelial cells lining normal vessels in KS lesions
(5, 7, 17, 20, 60, 64). In PEL and KS, HHV-8 is generally
present in a latent form (4, 11, 15, 17, 49, 61-64; M. Stürzl, G. Ascherl, C. Blasig, S. R. Opalenik, B. Ensoli,
and P. J. Browning, Letter, AIDS 12:1105-1106, 1998).
Recent observations indicate that both reactivation of HHV-8
infection (28, 40, 50) and impaired immunological control of HHV-8-infected circulating cells (43, 48; P. Monini,
M. C. Sirianni, M. Stürzl, M. Franco, L. Vincenzi, S. Topino, P. Leone, D. Goletti, P. Leone, M. Andreoni,
O. Barduagni, G. Rezza, and B. Ensoli, Abstr. 2nd Int. Workshop
KSHV/HHV-8 Relat. Agents, abstr. 30, 1999; M. C. Sirianni, L. Vincenzi, S. Topino, A. Giovannetti, F. Mazzetta, C. Alario, and B. Ensoli, Abstr. 2nd Int. Workshop KSHV/HHV-8 Relat. Agents, abstr. 29, 1999; M. C. Sirianni, C. Alario,
F. Libi, D. Scaramuzzi, S. Topino, F. Ensoli, and P. Monini, Abstr. 3rd Int. Workshop Kaposi's Sarcoma-Associated
Herpesvirus Relat. Agents, abstr. 105, 2000) lead to massive virus
spreading that is associated with development of KS (3, 4, 9, 19, 23, 33, 42, 54, 55, 59, 71). These observations are supported by
studies indicating that patients with AIDS-associated KS
undergoing highly active antiretroviral therapy can show clearance of
HHV-8 DNA from the circulation and that this is associated with KS
regression (34; D. A. Rizzieri, J. Liu, S. T. Traweek, and G. D. Miralles, Letter, Lancet
349:775-776, 1997; M. C. Sirianni, L. Vincenzi,
S. Topino, A. Giovannetti, F. Mazzetta, C. Alario, and B. Ensoli, Abstr. 2nd Int. Workshop KSHV/HHV-8 Relat. Agents, abstr. 29, 1999). In this context, our recent work has shown that latent HHV-8 is
reactivated in monocytes and B cells from persons with KS or at risk of
KS upon the exposure of peripheral blood mononuclear cells to specific
Th-1-type inflammatory cytokines (ICs) that are found to be increased
in persons with KS or at risk of KS (40).
There is evidence indicating that the lack of immunological control of
HHV-8 infection may involve not only immune depression but also
specific virus immune escape mechanisms. Recent studies, in fact, have
shown that the gene products of HHV-8 open reading frames (ORFs)
K3 and K5 are capable of downregulating major histocompatibility class
I (MHC-I) proteins and coactivation molecules, thereby allowing HHV-8-infected cells to escape both cytotoxic T-lymphocyte and natural
killer (NK) cell responses (10, 26, 29, 30). Viral mechanisms of immune evasion are likely to be important when immune depression is not yet apparent, and virus spreading and dissemination to tissues are essentially driven by virus reactivation upon IC stimulation. In addition, immune evasion is likely to be relevant also
for other HHV-8-associated diseases, such as MCD, the exacerbation and
worsening of which appear to be associated with increased HHV-8 viremic
levels (25, 46).
To ensure a prompt evasion of the immune response by cells undergoing
virus reactivation, ORFs K3 and K5 must be efficiently expressed
with early kinetics. In this context, HHV-8 reactivation is known to
depend on the induction of viral immediate-early (IE) genes whose
transcription is driven by host factors and is independent of de novo
viral protein synthesis (24, 35-37, 58, 67, 69, 74).
However, there are few data on the transcription pattern of HHV-8 ORFs
K3 and K5. In previous studies, both of these ORFs were shown to be
expressed with early kinetics upon virus reactivation in PEL cell lines
(36, 67). In addition, ORF K5 was shown to encode IE
transcripts in an HHV-8-positive, Epstein-Barr virus (EBV)-negative PEL
cell line (26), but not in PEL cells coinfected by HHV-8
and EBV (67, 74). However, the molecular pattern and
kinetics of K3 transcription have not yet been elucidated, and there
are no available data on K3 expression in KS tissue.
Here we show that K3 expression in EBV-negative PEL cells occurs
through the synthesis of multiple transcripts containing coding
sequences from viral ORFs K3 and 70. All transcripts appear to be
expressed at very early times upon virus reactivation. In addition,
resistance of the expression of a bicistronic transcript to the protein
synthesis inhibitor cycloheximide indicates that the ORF K8 gene
product is in part expressed through an IE RNA molecule. By contrast,
ORF K3 transcripts were undetectable by in situ hybridization in the
majority of latently infected spindle cells of KS lesions.
 |
MATERIALS AND METHODS |
Cell cultures.
BCBL-1 cells, obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, were cultured in RPMI 1640 containing 10% fetal calf serum
(FCS), 1 mM sodium pyruvate, and 50 µM
-mercaptoethanol. BC-1
cells (provided by Patrick Moore, Columbia University, New York, N.Y.)
were cultured in RPMI 1640 containing 15% FCS. Cells were split at a
density of 3 × 105/ml twice a week.
Induction of HHV-8 lytic replication in PEL cells.
Exponentially growing BCBL-1 cells (106/ml) were
resuspended at a density of 5 × 105/ml and
grown for an additional 24 h. HHV-8 lytic replication was then
induced in these cells by treatment with 20 ng of phorbol 12-myristate
13-acetate (TPA; Sigma, Milan, Italy)/ml for various periods of time
(53).
Determination of inhibition of protein synthesis by CHX.
Exponentially growing BCBL-1 cells (1.5 × 108) were collected, washed with
phosphate-buffered saline (PBS), suspended in methionine-free growth
medium (107/ml), and seeded in 24-well plates
(3 × 106/well). Cells were incubated for 45 min at 37°C prior to the addition of
[35S]methionine (25 µCi/well) and
cycloheximide (CHX; 10 or 100 µg/ml). Protein synthesis inhibition
was then determined after various periods of time by comparing the
percentage of trichloroacetic acid-insoluble
[35S]methionine from CHX-treated cultures with
that from untreated cells.
Purification of HHV-8 genomic DNA.
BCBL-1 cells (about
3 × 108) were cultured for 6 days in the
presence of TPA. Cell supernatants were cleared and filtered by using a
0.45-µm-pore-size membrane and then centrifuged for 2 h at
28,000 × g to collect the virus. The virus pellet was
suspended in 400 µl of Tris-EDTA-NaCl buffer (0.1 M Tris-HCl [pH
8.0], 0.01 M EDTA [pH 8.0], 0.1 M NaCl) containing 20 mM
MgCl2 and 250 IU of pancreatic DNase I
(Boehringer GmbH, Mannheim, Germany)/ml and incubated at 37°C for
1 h. DNase digestion was repeated three times with addition of
fresh DNase I on each occasion. At the end of the DNase digestion, EDTA
was added to a final concentration of 50 mM and the virus suspension
was rapidly heated to 95°C and incubated at this temperature for 10 min. The viral particles were then digested with proteinase K
(Boehringer GmbH; 0.4 mg/ml) in the presence of 2% (wt/vol) sodium
dodecyl sulfate at 37°C for 15 h. After proteinase K
inactivation at 95°C for 10 min, viral DNA was extracted by using
phenol and chloroform, ethanol precipitated, and digested with the
XbaI restriction enzyme.
Recombinant plasmids.
HHV-8 nut-1/T1.1, ORF
12/kaposin, and 18S ribosomal cDNA recombinant plasmids used as
probes for Northern blot analysis or for the screening of the
suppression subtractive hybridization (SSH) cDNA library (see below)
were described previously (39). Other probes used for
Northern blotting, screening of the SSH library, or in situ
hybridization were constructed by cloning PCR products amplified from
HHV-8 phage or plasmid clones obtained from a classic KS lesion genomic
library in the pCRII plasmid vector (Invitrogen, Carlsbad, Calif.). The
nucleotide boundaries of the probes used in the study are as follows:
ORF K3, nucleotides (nt) 18608 to 19609; ORF 70, nt 20137 to 21104; ORF
50, nt 72639 to 73299; ORF K5, nt 25871 to 26219; ORF 2, nt 17881 to
18598; and ORF K8, nt 74961 to 75243 (nucleotide enumeration as for
GenBank accession no. KSU75698).
Northern blot hybridization.
Total RNA was extracted from
BCBL-1 cells by using an RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer's instructions. Equal amounts of total
RNA (5 to 20 µg) were suspended in a buffer containing 40 mM
morpholinepropanesulfonic acid (MOPS; pH 7.0), 10 mM sodium acetate (pH
4.5), 10 mM EDTA (pH 8.0), 50% (vol/vol) formamide, and 2.2 M
formaldehyde; incubated at 65°C for 15 min; and chilled on ice. A
50% (vol/vol) glycerol solution containing 0.25% (wt/vol) bromophenol
blue and ethidium bromide was then added to the samples, and the RNA
was subjected to electrophoresis through formaldehyde-agarose gels,
transferred onto nylon membranes (Hybond N; Amersham, Little Chalfont,
United Kingdom), and hybridized to 32P-labeled
DNA probes by standard procedures.
SSH.
BCBL-1 cells (5 × 108) were
preincubated in the presence of CHX (10 µg/ml) for 30 min and induced
for 4 h with 20 ng of TPA/ml in the continuous presence of CHX.
Total RNA was then extracted and purified by using an RNeasy Midi Kit
(Qiagen). Poly(A)+ RNA was isolated by using an
Oligotex mRNA Midi Kit (Qiagen). cDNA synthesis and SSH (12,
13) were performed with a PCR-Select cDNA Subtraction Kit
(Clontech, Palo Alto, Calif.) according to the instructions of the
manufacturer. Prior to subtractive hybridization, cDNA from BCBL-1
cells (tester cDNA) was RsaI restricted and linked to
oligonucleotide adapters. To minimize the subtraction of BCBL-1 IE
cDNA, uninduced BC-1 cells were chosen as the source of driver (subtracting) cDNA because these cells are characterized by a very low
frequency of spontaneous reactivation (reference 74 and data not
shown). The first and second hybridization steps were performed with a
fivefold excess of RsaI-restricted driver cDNA
and a 1:1 ratio of RsaI-restricted tester and driver cDNAs,
respectively. Nested-PCR products from the subtracted cDNA were used as
32P-labeled probes for Southern blot
hybridization analysis of XbaI-digested HHV-8 DNA.
Construction and screening of the subtracted cDNA library.
SSH PCR products were cloned in the pCRII plasmid vector by using a TA
cloning kit (Invitrogen) and employed to transform competent One Shot
bacteria (Invitrogen). The titer of the resulting subtracted cDNA
library was determined to be about 2,500 ampicillin-resistant bacterial
colonies. A total of 315 randomly selected, individual colonies
were picked and screened with 32P-labeled HHV-8
subgenomic DNA probes specific for viral ORF 50, ORF K12, ORF K5, ORF
K8, ORF 2, or ORF K3 or with 32P-labeled HHV-8
DNA purified from BCBL-1 cell supernatants.
RACE.
The 5' and 3' boundaries of HHV-8 K3 transcripts were
determined by rapid amplification of cDNA ends (RACE) (21,
22), using a Marathon cDNA amplification kit (Clontech), with
cDNA from purified poly(A)+ RNA isolated from
BCBL-1 cells induced with TPA in the presence of CHX. PCR primers
internal to the SSH cDNA clone were as follows: SSH 1 (5'-AGAGATAGATCACGTCGCTG-3', nt 19219 to 19200), SSH 2 (5'-TATTGCCTCGGCTGACTTAC-3', nt 19398 to 19379), SSH 3 (5'-CTCGAGAACGTCCATAGAAG-3', nt 19522 to 19503), and SSH 4 (5'-TTAGACTGGTGGACTACTGC-3', nt 20146 to 20127) for amplification of 3'
cDNA ends and SSH I (5'-GCAGTAGTCCACCAGTCTAA-3', nt 20127 to
20146), SSH III (5'-CGTAGTGGCTCTATATGCGT-3', nt 20178 to
20197), and SSH IV (5'-GCCTGAGATACTGAAGTTCC-3', nt 20927 to 20946)
for amplification of 5' cDNA ends (nucleotide enumeration as for
GenBank accession no. KSU75698). PCR products were cloned into the
pCRII plasmid vector (Invitrogen) and analyzed by DNA sequencing.
Amplification of sequences internal to the K3 transcripts.
Regions internal to the 5' and 3' RACE boundaries were amplified with
primers K3ca (5'-TTAATGAAACATAAGGGCAGACG-3', nt 18608 to 18630) and K3cb (5'-ATGTTTCCGTTTGTACC-3', nt
21104 to 21088), spanning the ORF K3 stop codon and the ORF 70 ATG
(underlined), or with primers SSH V
(5'-CAGCGACGTGATCTATCTCT-3', nt 19251 to 19270) and SSH 5 (5'-GGAACTTCAGTATCTCAGGC-3', nt 20946 to 20927), which are
located in more internal regions of ORFs K3 and ORF 70, respectively
(nucleotide enumeration as for GenBank accession no. KSU75698). PCR
amplification was performed with a GeneAmp XL PCR kit for long-range
PCR (Perkin-Elmer, Branchburg, N.J.) according to the manufacturer's instructions.
DNA sequencing.
DNA sequencing was performed with an ABI 377 sequencer, using an ABI BigDye Terminator Cycle Sequencing Ready
Reaction Kit (Perkin-Elmer).
Immunofluorescence assay.
BCBL-1 cells were spotted onto
multitest slides (ICN, Aurora, Ohio) at a density of 5 × 104 per well, air dried, and fixed in 4%
paraformaldehyde for 20 min at room temperature. After permeabilization
with PBS containing 0.2% Triton X-100 for 10 min, the cells were
incubated in 100 mM glycine for 10 min and then in PBS containing 10%
FCS for 20 min. The cells were then incubated for 1 h with
anti-viral-interleukin-6 (vIL-6) rabbit polyclonal antibody (Advanced
Biotechnologies Inc., Columbia, Md.; 1:200 dilution) or control rabbit
nonimmune serum at 37°C. After three washes (10 min each) with PBS,
fluorescein isothiocyanate (FITC)-conjugated anti-rabbit immunoglobulin
G antibody (Sigma) was added. After a 1-h incubation at 37°C, the cells were washed three times with PBS and once with PBS containing evans blue (Sigma) as a counterstaining dye. For quantitation of
fluorescent cells, four microscopic fields (25× magnification) were
randomly collected for each sample with a cooled charge-coupled device
camera, and images were processed using OptiLab 2.6 software (Graphtek,
Mirmande, France) to evaluate the percentage of positive (FITC-stained)
cells present in each microscopic field.
In situ hybridization.
Bioptic samples from KS lesions were
fixed in PBS-buffered 4% paraformaldehyde at 4°C, dehydrated, and
paraffin embedded as previously described (65, 66). Thin
tissue sections (5 to 10 µm thick) were hybridized to antisense
35S-radiolabeled K3 or K8 RNA probes or to a
control
-actin RNA probe as previously described (39,
64). Briefly, the RNA probe solution (10 to 15 µl) was applied
to the deparaffinized tissue sections at an adjusted activity of 50,000 cpm/µl in hybridization buffer (50% deionized formamide, 0.3 M NaCl,
20 mM Tris-HCl [pH 7.4], 5 mM EDTA, 10 mM NaPO4
[pH 8.0], 10% dextran sulfate, 1× Denhardt's solution, 50 µg of
total yeast RNA/ml). Hybridization was carried out at 50°C for
16 h. At the end of the hybridization step, tissue sections were
washed at 50°C in 5× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium
citrate) containing 10 mM dithiothreitol; stringently washed at 60°C
in a solution containing 50% formamide, 2× SSC, and 0.1 M
dithiothreitol; covered with a film emulsion; and incubated for 14 days.
Prediction of K3 splicing pattern and transcriptional
promoters.
Analysis of the HHV-8 K3 locus for splicing
donor-acceptor sites and transcriptional start sites was
performed by the neural network method (45, 51, 52) with
the software from the Berkeley Drosophila Genome
Project (http://www.fruitfly.org/index.html).
Nucleotide sequence accession numbers.
The nucleotide
sequences of the K3 transcript cDNAs have been submitted to GenBank and
given the following accession numbers: T(lm)2, AF307519; T1, AF307581;
T2, AF307517; and T3, AF307516.
 |
RESULTS |
Analysis of HHV-8 ORF K3 expression.
Herpesvirus IE gene
transcription is driven by preexisting viral or host factors;
therefore, it can proceed in the absence of de novo protein
synthesis (32, 56). In contrast, efficient transcription
of herpesvirus delayed-early (DE) or late viral genes requires de novo
synthesis of viral transcriptional factors (32, 56).
The transcription pattern of HHV-8 ORF K3 was determined in latently
HHV-8-infected PEL-derived BCBL-1 cells that had been subjected to TPA
treatment, in the presence or absence of CHX, to induce replication of
the virus (39, 53). Since PEL cells have been shown to be
extremely sensitive to the toxic effects of CHX (36, 74),
BCBL-1 cells were maintained for various periods of time in the
presence or absence of a low (10 µg/ml) or high (100 µg/ml)
concentration of CHX and analyzed for both inhibition of protein
synthesis and cell survival. Cell protein synthesis was found to be
blocked at both CHX concentrations within the first 30 min of
treatment, as indicated by the very low percentage (<5%) of
35S incorporation by CHX-treated cells (data not
shown). The percentage of viable (i.e., trypan blue-excluding) cells
remained unchanged during the early hours of treatment; however, cell
viability was found to be significantly decreased after 8 h (70%
or fewer viable cells after 16 h). Since the loss of cell
viability was less pronounced at the low CHX concentration, all further
experiments were performed by treating BCBL-1 cells for up to 16 h
in the presence or absence of CHX at a concentration of
10 µg/ml.
To analyze the expression pattern of the K3 gene product, BCBL-1 cells
were cultured for various periods of time with or without
TPA, in the
presence or absence of CHX, and total RNA was analyzed
by Northern blot
hybridization with a DNA probe spanning HHV-8
ORF K3. To ensure a
maximal blockade of protein synthesis upon
virus reactivation, cells
were induced with TPA 30 min after CHX
addition.
Under these conditions, Northern blot analysis identified three major
K3 transcripts (T1, T2, and T3), with approximate sizes
of 2.5, 1.5, and 1.3 kb, respectively, and two low-intensity hybridization
bands of
lower mobility [T(lm)1 and T(lm)2] (Fig.
1A). In the
absence of
CHX, the expression of all K3 transcripts appeared
to be induced above
background levels at early times after TPA
induction and reached the
maximal level of expression between
4 and 8 h postinduction (Fig.
1A). The expression of the majority
of the K3 transcripts was clearly
inhibited by CHX at all times
post-TPA induction, indicating that the
majority of K3 transcripts
have an expression pattern typical of
herpesvirus DE genes (Fig.
1A). However, the 1.5-kb transcript (T2) was
consistently induced
above background levels at all times
postinduction, even in the
presence of CHX (Fig.
1A), and thus a novel
HHV-8 IE transcript
containing K3 coding sequences was identified. As a
control, hybridization
of the same blot with a probe specific for the
HHV-8 DE gene
nut-1/T1.1
(
39,
57,
68,
73)
produced a band that, as predicted, was
clearly sensitive to CHX
treatment (Fig.
1A).


View larger version (81K):
[in this window]
[in a new window]
|
FIG. 1.
Expression of ORF K3, nut-1/T1.1, vIL-6,
and 18S rRNA in TPA-induced BCBL-1 cells cultured in the presence or
absence of CHX. (A) Kinetics of induction of ORF K3 transcripts,
nut-1/T1.1 RNA, or 18S RNA by TPA in cells treated or
not treated with CHX. CHX (10 µg/ml) was added to BCBL-1 cells, and
after 30 min, cells were induced with TPA (20 ng/ml). Cell cultures
were harvested at the indicated time points after TPA induction, and
total RNA (10 µg) was analyzed by Northern blot hybridization with
the pCRII-K3 probe. Two low-intensity bands, corresponding to
low-mobility transcripts [T(lm)1 and T(lm)2], and three major
transcripts of higher mobility (T1, T2, and T3) were identified. The
membrane was stripped and rehybridized with probes specific for
nut-1/T1.1, as a control for inhibition by CHX of HHV-8
DE gene induction, or 18S RNA, as a control for the amount of sample
loaded on the gel. The positions of the 28S and 18S rRNAs, as molecular
size markers, are indicated. (B) Kinetics of induction of vIL-6 by TPA
in cells treated or not treated with CHX. (Upper panels) Left,
uninduced cell cultures grown in the absence of CHX; right, uninduced
cells incubated with a preimmune rabbit serum. (Lower panels) Left (TPA + CHX), cells induced with TPA in the presence of CHX; right (TPA),
cells induced with TPA in the absence of CHX. Pictures are
representative microscopic fields of FITC-stained cells counterstained
with evans blue (magnification, 100×). In the absence of CHX, vIL-6
expression in TPA-induced cells continued to increase, and a
significantly higher percentage of TPA-induced cells was found to be
positive for vIL-6 expression at 48 h postinduction (data not
shown). vIL-6 expression was quantified by analysis with a cooled
charge-coupled device camera and OptiLab 2.6 software, confirming that
viral protein synthesis was efficiently blocked in BCBL-1 cells induced
with TPA in the presence of CHX at the indicated time points (data not
shown).
|
|
To determine whether viral protein synthesis (including early viral
transcriptional activators) was completely blocked by
CHX in the cells
analyzed for K3 gene expression, aliquots of
the same cell cultures
were analyzed for expression of vIL-6 (
41,
44,
67) by an
immunofluorescence assay. As shown in Fig.
1B,
upon TPA induction,
vIL-6 expression showed a clear increase to
levels above the
background, reaching a peak at 8 to 16 h postinduction;
however,
this upregulation was absent in the cells treated with
CHX, confirming
that de novo viral protein synthesis was completely
inhibited by
CHX. These experiments showed that HHV-8 ORF K3 transcription
occurs through a complex program involving IE and DE viral
transcripts.
Isolation of IE K3 cDNA sequences by SSH.
To identify and
characterize the HHV-8 IE K3 transcript, total RNA from BCBL-1 cells
was subjected to SSH, a PCR-based technique that allows isolation of
cDNA sequences from genes that are differentially expressed on exposure
to specific stimuli (12, 13). To this end, BCBL-1 cells
were treated with CHX for 30 min and then induced with TPA for 4 h
in the continuous presence of CHX. Poly(A)+ cDNA
prepared from these cell cultures was digested with the RsaI
restriction enzyme and subjected to subtractive hybridization with
an excess of RsaI-restricted cDNA from uninduced cells (see Materials and Methods). To minimize subtraction of BCBL-1 IE cDNA sequences, the subtraction step was performed with cDNA from
uninduced BC-1 cells, a PEL cell line characterized by very-low-level
HHV-8 spontaneous reactivation (reference 74 and data not shown). These experimental conditions allowed the enrichment of
cDNA RsaI restriction fragments from HHV-8 genes whose
expression was induced upon virus reactivation in the presence of CHX.
Under these conditions, SSH yielded a smear underlying several discrete
DNA bands ranging in size from 0.3 to about 1 kb (data not shown).
To verify that the subtracted cDNA contained viral sequences from HHV-8
ORF K3, genomic HHV-8 DNA was purified from TPA-induced
BCBL-1
supernatants, digested with the
XbaI restriction
endonuclease,
and hybridized to the SSH cDNA that was used as a probe.
As expected,
this analysis identified two hybridization bands whose
sizes corresponded
to the two
XbaI HHV-8 DNA fragments
containing sequences from
ORF K3 (Fig.
2,
bands a and e). In addition, other bands with
sizes consistent with
XbaI restriction fragments containing other
viral IE genes,
including ORFs 50, K8, K8.1, and K8.2 (which all
encode the Rta
transactivator) (
24,
36,
37,
58,
67,
69,
74)
,
ORF K4.2, ORF K5, and ORF 45 (
26,
74), also hybridized
with the SSH cDNA probe (Fig.
2).


View larger version (40K):
[in this window]
[in a new window]
|
FIG. 2.
Isolation and identification of HHV-8 ORF K3 IE cDNA by
SSH. The SSH cDNA was used as a probe for hybridization of HHV-8
genomic DNA digested with the XbaI restriction
endonuclease. (A) Southern blot hybridization of HHV-8 genomic
DNA with the SSH cDNA probe. Viral genomic DNA extracted from
TPA-induced BCBL-1 cell supernatants (1 µg) was extensively
digested with XbaI, electrophoresed through a 0.8%
agarose gel, transferred to a nylon membrane, and hybridized with the
bulk of SSH cDNA labeled with 32P. Six bands (a to f)
reacting with the SSH cDNA probe, with sizes ranging from 1.8 to 10 kbp, were identified. The 10-kbp band corresponds to a
doublet of similarly sized restriction fragments (e and f) (see panel
B). Viral ORFs contained in XbaI restriction fragments a
to f (panel B) are indicated on the left side of the
autoradiogram. Sequences from ORF K3 are contained in bands
a and e. In addition, bands containing larger-sized fragments,
possibly corresponding to the largest XbaI restriction
fragments or to fragments containing viral terminal repeats, were also
detected. HindIII-digested lambda phage DNA was used as
a molecular size marker. The positions of the lambda DNA fragments are
indicated by dashes; the arrows point to the hybridization bands a to
f. The sizes of the DNA fragments are indicated in kilobase pairs. (B)
Diagram of HHV-8 XbaI (×) restriction pattern. DNA
fragments with sizes corresponding to the hybridization bands reacting
with the SSH cDNA probe (a to f) are indicated in bold. The sizes of
the reacting fragments (in kilobase pairs) and the encoded HHV-8 ORFs
are shown. Restriction fragments a and e contain sequences
from ORF K3. ORFs whose sequences are known to be present within HHV-8
IE transcripts are shown in black. Sequences from ORF 70 were
determined to be encompassed in the IE ORF K3 transcript (see text for
details). TR, terminal repeats.
|
|
To isolate the cDNA sequences hybridizing to ORF K3, the bulk of the
SSH cDNA was cloned in a plasmid vector and a representative
aliquot of
the resulting subtracted cDNA library was screened
with an HHV-8 DNA
genomic probe. Four of the several HHV-8-positive
colonies hybridized
with an ORF K3-specific probe. Notably, several
of the HHV-8-positive
colonies hybridized with probes specific
for other HHV-8 IE genes,
including ORF 50 and ORF K5, and six
colonies reacted with a
probe specific for ORF K8, whose sequences
have been shown to be
present in IE transcripts encoding the viral
transactivator Rta
(
24,
36,
37,
58,
69,
74). In contrast,
none of the
colonies hybridized with a probe for the HHV-8 DE
ORF 2 viral
dihydrofolate reductase (vDHFR) gene (which is adjacent
to ORF K3 in
the HHV-8 genome [Fig.
2B]) (
67) or with the HHV-8
latency-associated ORF K12 (
64,
73), showing that the SSH
cDNA pool was indeed enriched in HHV-8 IE cDNA
sequences.
Characterization of the IE ORF K3 SSH cDNA.
By DNA sequencing
it was determined that all four SSH K3-positive recombinant clones
carried the same cDNA fragment, spanning HHV-8 sequences between two
RsaI restriction sites present at nt 19241 and 21092 in the
viral genome (Fig. 3). The SSH cDNA insert contained sequences corresponding to both ORF K3 and ORF 70, which encodes the HHV-8 thymidylate synthase (TS) homologue (57). ORF 70 coding sequences from nt 20301 to 20842 were
removed by in-frame splicing, and a large part of the noncoding
sequence between ORFs 70 and K3 (nt 19612 to 20088) was also deleted by a splicing event resulting in a three-exon cDNA fragment (Fig. 3).

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 3.
Molecular arrangement of the SSH K3 cDNA. The
arrangement of the four SSH cDNA clones that were positive at screening
with the ORF K3-specific probe is shown. The four clones were identical
and spanned sequences between two RsaI sites present
within ORFs K3 and 70. The nucleotide positions of exon-intron
junctions (enumerated as for GenBank accession no. KSU75698) are
indicated. Splicing donor and acceptor sites were detected by neural
network analysis (52) at the exon-intron junctions (data
not shown).
|
|
To confirm that the K3 IE transcript corresponded to the SSH cDNA
clone, the RNA from the experiment shown in Fig.
1A was
hybridized with
a probe specific for ORF 70. This analysis proved
that the IE 1.5-kb K3
transcript, T2, also contained sequence
from ORF 70 (Fig.
4). In addition, the DE 2.5-kb
transcripts,
T(lm)2 and T1, also reacted with the ORF 70 probe (Fig.
4). The
low sensitivity of this hybridization, however, did not allow
the detection of the presence of ORF 70 sequences in the T3 transcript,
which, as indicated by subsequent analysis, also contained stretches
of
sequences from HHV-8 ORF 70 (see below).

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 4.
Detection of ORF 70 sequences in ORF K3 transcripts. The
RNA from the experiment shown in Fig. 1A was hybridized to an ORF
70-specific DNA probe. Sequences reacting with the ORF 70 probe were
detected in the IE transcript T2 and in the DE transcript T1. Similar
results were obtained upon rehybridization of the Northern blot
membrane shown in Fig. 1A (data not shown).
|
|
Mapping of 5' and 3' K3 mRNA boundaries by RACE.
To determine
the 5' and 3' ends of the HHV-8 K3 transcripts, cDNA from BCBL-1 cells
induced for 4 h with TPA in the presence of CHX was subjected to
RACE (21, 22). To this end, PCR primers designed against
regions internal to the second exon of the SSH K3 cDNA clone
were used in combination with primers specific for 5' or 3' RACE
oligonucleotide adapters (Fig. 5A,
primers SSH I, SSH 4, AP1, and AP2). RACE resulted in several 5' and 3'
amplicons (Fig. 5B).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
Diagram of the amplicons obtained by RACE. (A) The HHV-8
genomic region containing ORFs K3 and 70 and the structure of the SSH
cDNA clone with the primers employed for RACE analysis are shown. (B)
Molecular structure of the 5' and 3' RACE amplicons. Oligonucleotide
primers specific for exon 2 (primers SSH I and SSH 4) and RACE adapters
(primers AP1 and AP2) produced three 5' amplicons (5'a, 5'b, and 5'c)
and two 3' amplicons (3'a and 3'b). The principal features of the 5'
and 3' RACE products are depicted, including boundaries of 5' or 3'
ends, splicing pattern, presence of ATG or stop codons from ORF K3 or
ORF 70, and 3' poly(A) sequences (AAA). Primers SSH 1 to 3 and SSH III
and IV were also used in combination with adapter primers AP2 and AP1,
respectively, producing unspliced amplicons exhibiting the same 5' or
3' RACE boundaries as the amplicons shown in this figure (data not
shown). It is unlikely that unspliced amplicons were obtained upon
amplification of contaminant DNA; in fact, (i) BCBL-1 cDNA was obtained
from poly(A)+ purified RNA, (ii) the cDNA preparation was
negative for amplification of genomic -actin DNA sequences (data not
shown), (iii) ligation of RACE adapters requires DNA blunt ends that
are infrequently found at randomly nicked contaminant DNA termini, (iv)
the unspliced 3' RACE clone (3'a) has the typical mRNA poly(A) sequence
that is not found on the HHV-8 genome, and (v) the 5' RACE unspliced
amplicon (5'b) shows several alternative and clustered 5' ends that are
usually found upon mapping of transcriptional start sites on cDNA
molecules. (Nucleotide enumeration as for GenBank accession no.
KSU75698.)
|
|
DNA sequencing of PCR products from 5' RACE identified three different
amplicons (Fig.
5B, amplicons 5'a, 5'b, and 5'c). Two
of these
amplicons (amplicons 5'a and 5'b) were unspliced, and
one (amplicon
5'c) had the same splicing pattern as the IE SSH
K3 cDNA clone (Fig.
5B). The 5' boundary of one of the unspliced
forms (amplicon 5'a) and
of the IE spliced form (amplicon 5'c)
overlapped the ORF 70 ATG at nt
21104, whereas the other unspliced
amplicon (amplicon 5'b) corresponded
to an mRNA molecule that
was transcribed from a downstream promoter,
internal to ORF 70,
with four putative transcriptional start sites
mapping from nt
20988 to 21004 (Fig.
5B). 3' RACE analysis identified
an unspliced
polyadenylated amplicon as well as a polyadenylated
amplicon exhibiting
the same splicing pattern as the SSH cDNA (Fig.
5B,
amplicons
3'a and 3'b, respectively). Amplicon 3'b showed two
alternative
polyadenylation sites, at nt 18577 and 18595, located
immediately
downstream of the stop codon of ORF
K3.
As shown in Table
1, the most abundant
amplicons obtained by RACE (amplicons 5'c and 3'b) had the same
splicing pattern as
the IE SSH K3 cDNA clone. Since RACE was performed
with cDNA obtained
in the presence of CHX, this further confirmed that
the IE HHV-8
K3 transcript corresponded to the SSH K3 cDNA clone.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Percentages of 5' and 3' RACE clones obtained with cDNA
from BCBL-1 cells induced with TPA for 4 h in the continuous
presence of CHXa
|
|
Additional primers specific for exons 1 and 3 (Fig.
5A) yielded, as
expected, unspliced amplicons with the same DNA ends as
the amplicons
obtained with primers internal to exon 2 (data not
shown). All RACE
amplicons were reamplified with nested-PCR primers,
and the sequences
of the nested-RACE fragments proved to be identical
to those of the
unnested-RACE products (data not
shown).
Molecular arrangement of the K3 transcripts.
To characterize
the molecular arrangement of the viral transcripts, amplification of
the full-length K3 cDNAs was attained by long-range reverse
transcription-PCR with primers spanning the ORF 70 ATG and the ORF K3
stop codons, i.e., with primers specific for the 5' and 3' RACE
boundaries (primers K3ca and K3cb [Fig.
6]). This analysis, which was performed
with cDNA from BCBL-1 cells that had been induced with TPA for 4 h
in the presence of CHX, yielded two amplicons, corresponding to the IE
doubly spliced SSH K3 cDNA clone (the most abundant transcript when CHX
treatment was applied) and to a singly spliced form lacking exon 2 because of alternative splicing (Fig. 6B). These primers, however, did not allow amplification of cDNA from unspliced transcripts because these transcripts lacked sequences from the ORF 70 ATG (Fig. 5B) and/or
were expressed at very low levels in the presence of CHX (Fig. 1A and
Table 1). Amplification of cDNA sequences corresponding to the
unspliced transcripts was, nevertheless, achieved by PCR with
more-recessed primers (SSH V and SSH 5 [Fig. 6]). Overall, a total of
four major transcripts with alternative splicing and/or transcriptional
start sites, carrying sequences from both HHV-8 ORFs K3 and 70, were
identified by combining data from RACE and long-range PCR analysis
(Fig. 6B). The molecular sizes of these transcripts indicated that they
corresponded to the low-mobility hybridization band T(lm)2, to the
2.5-kb band (T1), to the 1.5-kb IE transcript (T2), and to the 1.3-kb
band (T3) (Fig. 6B).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 6.
Molecular structure of ORF K3 transcripts. (A) Diagram
of the HHV-8 ORF K3-ORF 70 locus and of the SSH K3 cDNA clone. Primers
K3cb and K3ca, which were designed to contain the ATG from ORF
70 and the stop codon from ORF K3, respectively, and primers SSH 5 and
SSH V, designed in regions internal to the SSH clone, are indicated.
The 5' and 3' RACE boundaries of the transcripts are shown. (B)
Structure of the transcripts as deduced by combining data from RACE
with that from PCR analysis with primers specific for RACE ends or
internal to the SSH K3 cDNA clone. The major features of the
transcripts are described; solid lines represent sequences amplified
with primer pair K3ca-K3cb or SSH 5-SSH V, and broken lines represent
sequences identified by RACE (see also Fig. 5B). The relative abundance
of the transcripts obtained in the presence of CHX is depicted in the
Northern blot inset (B, left); the various transcripts were assigned to
the respective Northern blot bands on the basis of their molecular
sizes. The sizes of the cDNA sequences are also shown (as calculated
for the 3' boundary present at nt 18577). (Nucleotide enumeration as
for GenBank accession no. KSU75698.)
|
|
Two of these transcripts

namely, the T(lm)2 unspliced form and the IE
doubly spliced transcript T2

were shown to contain the
ATG and the
stop codons from both ORFs 70 and K3; therefore, they
have the
molecular arrangement typical of bicistronic transcripts
(Fig.
6B).
Although these transcripts have the potential to express
both of the
ORFs, depending on the ATG usage, expression of a
functional TS by the
IE transcript is unlikely to occur because
of extensive deletion of ORF
70 coding sequences by RNA splicing.
The start site of the 2.4-kb
unspliced DE transcript T1 was found
to be located downstream of the
ORF 70 ATG; however, this transcript
potentially encodes a truncated TS
homologue, starting at an internal
in-frame ATG (nt 20852) (Fig.
6B),
as well as a complete ORF K3
product. By contrast, the 1.3-kb singly
spliced DE transcript,
T3, contained both the ORF 70 and ORF K3 ATGs
but lacked the stop
codon from ORF 70. Depending on the ATG used, this
transcript
can encode the ORF K3 product and/or a fusion peptide; the
latter,
however, is truncated at nt 19498 because of a K3 out-of-frame
translation pattern (Fig.
6B).
Notably, three of the four transcripts had a 5' RACE end mapping to the
ORF 70 ATG (Fig.
6B). However, as discussed below,
further analysis
indicated that the 5' RACE end of these transcripts
likely corresponds
to a reverse transcriptase pausing site, the
true transcriptional start
sites being located further downstream
in the HHV-8
genome.
Expression of ORF K3 in KS lesions.
HHV-8 is present as a
latent virus in the majority of infected KS spindle cells or
endothelial cells lining lesional vessels, and it replicates
productively in a small percentage of cells present in the lesions,
including tissue-infiltrating lymphomonocytes (4, 47,
62-64; M. Stürzl, G. Ascherl, C. Blasig, S. R. Opalenik, B. Ensoli, and P. J. Browning, Letter, AIDS
12:1105-1106, 1998). Transcription of HHV-8 IE genes in KS
lesions is, therefore, predicted to occur only in the small fraction of
cells undergoing productive virus replication. To examine the
expression pattern of HHV-8 ORF K3 in KS, seven KS lesions were
analyzed by in situ hybridization (ISH) with an ORF K3-specific
antisense RNA probe. K3 transcripts were found to be expressed by only
a few cells in two of the seven lesions analyzed (Fig.
7a and b and data not shown), whereas the other five lesions were found to be negative (data
not shown). A scattered pattern of expression by the HHV-8 ORF K8 (Fig.
7c), which was used as a control for HHV-8 early-gene expression, was
also evident. In particular, sequences from this viral ORF are present
in both IE transcripts (24, 36, 37, 58, 69, 74), which in
BCBL-1 cells accumulate within 12 h of TPA induction
(58), as well as DE transcripts encoding the viral
transactivator K-bZIP (35, 58). ISH signals from ORF K3
were less frequent and less intense than those from ORF K8,
suggesting that ORF K3 RNA is expressed at low levels in KS lesions
(Fig. 7). By contrast, control (normal) skin above KS lesions was
consistently negative for both ORF K3 and ORF K8 expression (Fig. 7d
and data not shown).

View larger version (102K):
[in this window]
[in a new window]
|
FIG. 7.
Detection of transcripts from HHV-8 ORF K3 in a KS
lesion by ISH. Microscopic bright fields (left panels) and
corresponding dark fields (right panels) are shown (magnification,
×200). Upon hybridization with an HHV-8 ORF K3 antisense probe,
low-intensity signals were detected in few cells that were scattered
(a, arrowheads) or formed swirl-like structures within the lesion (b,
arrow). Scattered cells with intense ISH signals (c, arrows) were
detected in the same lesion upon hybridization with an antisense probe
specific for the IE-DE HHV-8 ORF K8. No signals from HHV-8 ORF K3 or K8
were detected in normal skin above the KS lesion (panel d and data not
shown). Consecutive sections were subjected to ISH with a control
antisense -actin RNA probe with positive results (data not shown).
|
|
 |
DISCUSSION |
In this study, we have shown that transcription of the
MHC-I-downregulating HHV-8 ORF K3 in PEL cells is induced with kinetics typical of a viral early gene, confirming recent data pointing to
virus-mediated downregulation of MHC-I molecules as an event associated
with early phases of virus replication (26, 36, 67).
Several early viral transcripts containing coding sequences from ORF K3
were identified, some of which showed a typical bicistronic structure.
Although alternative ATG usage may enable bicistronic messengers to
express the HHV-8 TS homologue, this is highly unlikely to occur for
one of the bicistronic RNA molecules, from which a large part of the TS
coding sequence from ORF 70 has been removed by RNA splicing. Indeed,
this bicistronic molecule appears to play a key role in the
transcriptional program leading to early induction of the K3 product;
in fact, its expression was found to occur in the absence of de novo
protein synthesis. By contrast, expression of all other K3 transcripts
apparently requires newly synthesized factors. These data
indicate that HHV-8 has evolved mechanisms to ensure a prompt and
modulated expression of the K3 gene product through both IE and DE
transcripts. Viral products downregulating MHC-I molecules are known to
be encoded by early genes in other herpesviruses as well, including
herpes simplex virus and cytomegalovirus (see references
27 and 31 and references cited therein). In
fact, prompt immune evasion of productively infected cells is required
for herpesvirus reactivation, as opposed to the efficient busting of
cytotoxic T-lymphocyte responses by intermittent virus reactivation
occurring throughout the host's life span (1, 6, 72).
Notably, previous work and the present data indicate that HHV-8 ORFs K3
and K5 are expressed through both IE and DE transcripts in
EBV-free PEL cell lines but only through DE transcripts in HHV-8- and
EBV-coinfected cells (26, 67, 74), suggesting that EBV may
interfere with the expression of some HHV-8 IE transcripts upon virus reactivation.
HHV-8 ORF K3 expression appears to occur through a complex
transcriptional program that is likely to be modulated in many ways. In
fact, several of the features of the HHV-8 K3 transcripts, including
alternative donor splicing sites and alternative ATG usage, are
possible targets of regulatory mechanisms tuning the expression of the
K3 product. In addition, ORF K3 expression appears to be modulated
through the activation of multiple transcriptional promoters. In fact,
two different 5' ends were identified, one mapping to a region internal
to ORF 70 coding sequences and the other at the ORF 70 ATG. In
particular, three of four K3 transcripts, including the IE doubly
spliced RNA molecule, the DE spliced RNA molecules, and one of the
unspliced transcripts, appeared to have been initiated at the first
nucleotide of the ATG from ORF 70. This finding may suggest that these
transcripts originate via the induction of a common IE large RNA
precursor to undergo differential splicing by preexisting or de
novo-synthesized splicing factors. This view, however, is in contrast
with the DE kinetics of expression of the unspliced transcript. Indeed,
neural network analysis of the HHV-8 K3 locus (45, 51) has
identified in this region several additional transcriptional promoters,
and preliminary reverse transcription-PCR analysis has indicated that
these K3 transcripts are likely to be initiated within downstream
sequences located between ORFs 70 and K4 (data not shown). Thus, the 5' RACE ends of these transcripts may reflect the presence of a strong pausing site for reverse transcriptase, leading to premature cDNA termination. Additional studies are therefore required to fully elucidate the transcriptional patterns of these viral transcripts and
their coding potentials.
The transcriptional factors responsible for inducing HHV-8 IE and DE K3
transcripts remain to be identified; however, by analogy with the other
herpesviruses, it can be anticipated that activation of the IE
transcript is dependent on housekeeping host genes, whereas the DE K3
transcripts are most likely induced by virus-encoded transcription
factors. In this context, the transcription factor from the IE ORF 50, Rta, is known to activate several viral transcriptional promoters,
including the K5 promoter (26), resulting in virus reactivation (24, 36, 37, 69). Since several studies
indicate that active and prolonged HHV-8 reactivation is predictive of KS development (28, 40, 42, 54, 55, 71) or is associated with MCD recrudescence (25, 46), these viral factors,
together with the ORF K3 product, may represent key factors in HHV-8 pathogenicity.
HHV-8 ORF K3 was found to be expressed at low levels only by rare cells
present in KS lesions. Since only a few types of cells, including
lymphomonocytes, are productively infected by HHV-8 in KS tissue
(4, 47, 62; M. Stürzl, G. Ascherl, C. Blasig, S. R. Opalenik, B. Ensoli, and P. J. Browning, Letter, AIDS
12:1105-1106, 1998), these data are in agreement with the
pattern of expression expected for a lytic IE or DE viral gene.
However, since the vast majority of cells present in lesions were found
to be negative for ORF K3 expression, these data also point to
additional, as-yet-unknown mechanisms ensuring immune evasion to
latently infected KS spindle cells. KS lesions are, in fact,
infiltrated by activated (e.g., gamma-interferon-expressing)
monocytes/macrophages and CD4+ and
CD8+ T cells, as well as by NK cells; however,
these effector cells are incapable of clearing infected cells from
lesions (18, 19, 59). One of the possible mechanisms for
immune evasion of latently infected KS spindle cells is related to the
expression of the HHV-8 FLICE-inhibitory protein homologue (vFLIP)
(2, 16, 70), which, in fact, is inversely correlated with
cell apoptosis in KS lesions (63) and has been shown to
inhibit FAS-mediated cell killing by CD8+ T cells
in a murine model (16). Other observations, however, point
to host mechanisms. In particular, our recent work indicates a
decreased NK cell cytotoxic activity in KS patients (M. C. Sirianni, L. Vincenzi, S. Topino, A. Giovannetti, F. Mazzetta, C. Alario, and B. Ensoli, Abstr. 2nd Int. Workshop KSHV/HHV-8 Relat.
Agents, abstr. 29, 1999) and the upregulation of killing-inhibitory
receptors (KIR) both in a subset of CD8+ T cells
and in NK cells from persons with KS or at risk of KS (M. C. Sirianni, C. Alario, F. Libi, D. Scaramuzzi, S. Topino, F. Ensoli, and
P. Monini, Abstr. 3rd Int. Workshop Kaposi's Sarcoma-Associated Herpesvirus Relat. Agents, abstr. 105, 2000).
Early expression of HHV-8 ORFs K3 and K5, leading to prompt
downregulation of MHC-I proteins and coactivation molecules (10, 26, 29, 30), may be crucial to KS development. First, this may
represent a potent mechanism for immune evasion of lytically infected
lymphomonocytes infiltrating KS lesions; these cells, in turn, may be
required for virus transmission and long-lasting latent infection of KS
spindle cells, as suggested by the loss of HHV-8 DNA from KS cells upon
culture in vitro (14, 38; C. Lebbè, P. de Cremoux,
M. Rybojad, C. Costa Da Cunha, P. Morel, and F. Calvo, Letter, Lancet
345:1180, 1995). Second, HHV-8 reactivation by the ICs
present in KS (40) leads to peripheral blood viremia
and virus dissemination in tissues that can precede both overt
immunosuppression and KS development (3, 4, 9, 19, 33, 42, 59,
71). Thus, prompt and efficient immune evasion by cells
undergoing virus reactivation may be a key mechanism for HHV-8
spreading during the inapparent phase that precedes KS development.
Therefore, agents directed at blocking the expression of the HHV-8 K3
gene product or at inhibiting its biological function may be exploited
for the prevention of HHV-8-associated diseases in infected individuals.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from the AIDS Project of the
Italian Ministry of Health to B. Ensoli, A. Caputo, and E. Cassai; by a
grant from the "Associazione Italiana per la Ricerca sul Cancro"
(AIRC, Milan) to B. Ensoli; and by the Biofuture program of the German
Ministry of Education and Research (BMBF) and the Deutsche Krebshilfe
(Mildred Scheel Stifung) to M. Stürzl. P. Rimessi was the
recipient of a postdoctoral fellowship in E. Cassai's laboratory.
We thank A. Lippa and F. M. Regini for editorial assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Virology, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. Phone: 39-06-49903209. Fax: 39-06-49903002. E-mail: ensoli{at}iss.it.
 |
REFERENCES |
| 1.
|
Arvin, A. M.
1996.
Varicella-zoster virus, p. 2547-2582.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 2.
|
Bertin, J.,
R. C. Armstrong,
S. Ottilie,
D. A. Martin,
Y. Wang,
S. Banks,
G. H. Wang,
T. G. Senkevich,
E. S. Alnemri,
B. Moss,
M. J. Lenardo,
K. J. Tomaselli, and J. I. Cohen.
1997.
Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis.
Proc. Natl. Acad. Sci. USA
94:1172-1176[Abstract/Free Full Text].
|
| 3.
|
Blackbourn, D. J.,
E. T. Lennette,
J. Ambroziak,
D. V. Mourich, and J. A. Levy.
1998.
Human herpesvirus 8 detection in nasal secretions and saliva.
J. Infect. Dis.
177:213-216[Medline].
|
| 4.
|
Blasig, C.,
C. Zietz,
B. Haar,
F. Neipel,
S. Esser,
N. H. Brockmeyer,
E. Tschachler,
S. Colombini,
B. Ensoli, and M. Stürzl.
1997.
Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8.
J. Virol.
71:7963-7968[Abstract].
|
| 5.
|
Boshoff, C.,
T. F. Schulz,
M. M. Kennedy,
A. K. Graham,
C. Fisher,
A. Thomas,
J. O. McGee,
R. A. Weiss, and J. J. O'Leary.
1995.
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells.
Nat. Med.
1:1274-1278[CrossRef][Medline].
|
| 6.
|
Britt, W. J., and C. A. Alford.
1996.
Cytomegalovirus, p. 2493-2523.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 7.
|
Cesarman, E.,
Y. Chang,
P. S. Moore,
J. W. Said, and D. M. Knowles.
1995.
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.
N. Engl. J. Med.
332:1186-1191[Abstract/Free Full Text].
|
| 8.
|
Chang, Y.,
E. Cesarman,
M. S. Pessin,
F. Lee,
J. Culpepper,
D. M. Knowles, and P. S. Moore.
1994.
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.
Science
266:1865-1869[Abstract/Free Full Text].
|
| 9.
|
Corbellino, M.,
L. Poirel,
G. Bestetti,
M. Pizzuto,
J. T. Aubin,
M. Capra,
C. Bifulco,
E. Berti,
H. Agut,
G. Rizzardini,
M. Galli, and C. Parravicini.
1996.
Restricted tissue distribution of extralesional Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS patients with Kaposi's sarcoma.
AIDS Res. Hum. Retrovir.
12:651-657[Medline].
|
| 10.
|
Coscoy, L., and D. Ganem.
2000.
Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis.
Proc. Natl. Acad. Sci. USA
97:8051-8056[Abstract/Free Full Text].
|
| 11.
|
Davis, M. A.,
M. A. Stürzl,
C. Blasig,
A. Schreier,
H. G. Guo,
M. Reitz,
S. R. Opalenik, and P. J. Browning.
1997.
Expression of human herpesvirus 8-encoded cyclin D in Kaposi's sarcoma spindle cells.
J. Natl. Cancer Inst.
89:1868-1874[Abstract/Free Full Text].
|
| 12.
|
Diatchenko, L.,
S. Lukyanov,
Y. F. Lau, and P. D. Siebert.
1999.
Suppression subtractive hybridization: a versatile method for identifying differentially expressed genes.
Methods Enzymol.
303:349-380[CrossRef][Medline].
|
| 13.
|
Diatchenko, L.,
Y. F. Lau,
A. P. Campbell,
A. Chenchik,
F. Moqadam,
B. Huang,
S. Lukyanov,
K. Lukyanov,
N. Gurskaya,
E. D. Sverdlov, and P. D. Siebert.
1996.
Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries.
Proc. Natl. Acad. Sci. USA
93:6025-6030[Abstract/Free Full Text].
|
| 14.
|
Dictor, M.,
E. Rambech,
D. Way,
M. Witte, and N. Bendsoe.
1996.
Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) DNA in Kaposi's sarcoma lesions, AIDS Kaposi's sarcoma cell lines, endothelial Kaposi's sarcoma simulators, and the skin of immunosuppressed patients.
Am. J. Pathol.
148:2009-2016[Abstract].
|
| 15.
|
Dittmer, D.,
M. Lagunoff,
R. Renne,
K. Staskus,
A. Haase, and D. Ganem.
1998.
A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus.
J. Virol.
72:8309-8315[Abstract/Free Full Text].
|
| 16.
|
Djerbi, M.,
V. Screpanti,
A. I. Catrina,
B. Bogen,
P. Biberfeld, and A. Grandien.
1999.
The inhibitor of death receptor signaling, FLICE-inhibitory protein, defines a new class of tumor progression factors.
J. Exp. Med.
190:1025-1032[Abstract/Free Full Text].
|
| 17.
|
Dupin, N.,
C. Fisher,
P. Kellam,
S. Ariad,
M. Tulliez,
N. Franck,
E. van Marck,
D. Salmon,
I. Gorin,
J. P. Escande,
R. A. Weiss,
K. Alitalo, and C. Boshoff.
1999.
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma.
Proc. Natl. Acad. Sci. USA
96:4546-4551[Abstract/Free Full Text].
|
| 18.
| Ensoli, B., P. Monini, and M. Stürzl.
Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv.
Cancer Res., in press.
|
| 19.
|
Fiorelli, V.,
R. Gendelman,
M. C. Sirianni,
H. K. Chang,
S. Colombini,
P. D. Markham,
P. Monini,
J. Sonnabend,
A. Pintus,
R. C. Gallo, and B. Ensoli.
1998.
-Interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection?
Blood
91:956-967[Abstract/Free Full Text].
|
| 20.
|
Foreman, K. E.,
P. E. Bacon,
E. D. Hsi, and B. J. Nickoloff.
1997.
In situ polymerase chain reaction-based localization studies support role of human herpesvirus-8 as the cause of two AIDS-related neoplasms: Kaposi's sarcoma and body cavity lymphoma.
J. Clin. Investig.
99:2971-2978[Medline].
|
| 21.
|
Frohman, M. A.
1993.
Rapid amplification of complementary DNA ends for generation of full-length complementary DNAs: thermal RACE.
Methods Enzymol.
218:340-356[Medline].
|
| 22.
|
Frohman, M. A.,
M. K. Dush, and G. R. Martin.
1988.
Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer.
Proc. Natl. Acad. Sci. USA
85:8998-9002[Abstract/Free Full Text].
|
| 23.
|
Gao, S. J.,
L. Kingsley,
D. R. Hoover,
T. J. Spira,
C. R. Rinaldo,
A. Saah,
J. Phair,
R. Detels,
P. Parry,
Y. Chang, and P. S. Moore.
1996.
Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.
N. Engl. J. Med.
335:233-241[Abstract/Free Full Text].
|
| 24.
|
Gradoville, L.,
J. Gerlach,
E. Grogan,
D. Shedd,
S. Nikiforow,
C. Metroka, and G. Miller.
2000.
Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line.
J. Virol.
74:6207-6212[Abstract/Free Full Text].
|
| 25.
|
Grandadam, M.,
N. Dupin,
V. Calvez,
I. Gorin,
L. Blum,
S. Kernbaum,
D. Sicard,
Y. Buisson,
H. Agut,
J. P. Escande, and J. M. Huraux.
1997.
Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells.
J. Infect. Dis.
175:1198-1201[Medline].
|
| 26.
|
Haque, M.,
J. Chen,
K. Ueda,
Y. Mori,
K. Nakano,
Y. Hirata,
S. Kanamori,
Y. Uchiyama,
R. Inagi,
T. Okuno, and K. Yamanishi.
2000.
Identification and analysis of the K5 gene of Kaposi's sarcoma-associated herpesvirus.
J. Virol.
74:2867-2875[Abstract/Free Full Text].
|
| 27.
|
Hill, A.,
P. Jugovic,
I. York,
G. Russ,
J. Bennink,
J. Yewdell,
H. Ploegh, and D. Johnson.
1995.
Herpes simplex virus turns off the TAP to evade host immunity.
Nature
375:411-415[CrossRef][Medline].
|
| 28.
|
Hudnall, S. D.,
P. L. Rady,
S. K. Tyring, and J. C. Fish.
1998.
Serologic and molecular evidence of human herpesvirus 8 activation in renal transplant recipients.
J. Infect. Dis.
178:1791-1794[CrossRef][Medline].
|
| 29.
|
Ishido, S.,
C. Wang,
B.-S. Lee,
G. B. Cohen, and J. U. Jung.
2000.
Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.
J. Virol.
74:5300-5309[Abstract/Free Full Text].
|
| 30.
|
Ishido, S.,
J. K. Choi,
B. S. Lee,
C. Wang,
M. DeMaria,
R. P. Johnson,
G. B. Cohen, and J. U. Jung.
2000.
Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein.
Immunity
13:365-374[CrossRef][Medline].
|
| 31.
|
Jones, T. R.,
E. J. Wiertz,
L. Sun,
K. N. Fish,
J. A. Nelson, and H. L. Ploegh.
1996.
Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains.
Proc. Natl. Acad. Sci. USA
93:11327-11333[Abstract/Free Full Text].
|
| 32.
|
Kieff, E.
1996.
Epstein-Barr virus and its replication, p. 2343-2353.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 33.
|
LaDuca, J. R.,
J. L. Love,
L. Z. Abbott,
S. Dube,
A. E. Freidman-Kien, and B. J. Poiesz.
1998.
Detection of human herpesvirus 8 DNA sequences in tissues and bodily fluids.
J. Infect. Dis.
178:1610-1615[CrossRef][Medline].
|
| 34.
|
Lebbè, C.,
L. Blum,
C. Pellet,
G. Blanchard,
O. Verola,
P. Morel,
O. Danne, and F. Calvo.
1998.
Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
AIDS
12:F45-F49[CrossRef][Medline].
|
| 35.
|
Lin, S.-F.,
D. R. Robinson,
G. Miller, and H.-J. Kung.
1999.
Kaposi's sarcoma-associated herpesvirus encodes a bZIP protein with homology to BZLF1 of Epstein-Barr virus.
J. Virol.
73:1909-1917[Abstract/Free Full Text].
|
| 36.
|
Lukac, D. M.,
J. R. Kirshner, and D. Ganem.
1999.
Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells.
J. Virol.
73:9348-9361[Abstract/Free Full Text].
|
| 37.
|
Lukac, D. M.,
R. Renne,
J. R. Kirschner, and D. Ganem.
1998.
Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein.
Virology
252:304-312[CrossRef][Medline].
|
| 38.
|
Monini, P.,
A. Rotola,
L. de Lellis,
A. Corallini,
P. Secchiero,
A. Albini,
R. Benelli,
C. Parravicini,
G. Barbanti-Brodano, and E. Cassai.
1996.
Latent BK virus infection and Kaposi's sarcoma pathogenesis.
Int. J. Cancer
66:717-722[CrossRef][Medline].
|
| 39.
|
Monini, P.,
F. Carlini,
M. Stürzl,
P. Rimessi,
F. Superti,
M. Franco,
G. Melucci-Vigo,
A. Cafaro,
D. Goletti,
C. Sgadari,
S. Buttò,
P. Leone,
P. Leone,
C. Chiozzini,
C. Barresi,
A. Tinari,
A. Bonaccorsi,
M. R. Capobianchi,
M. Giuliani,
A. Di Carlo,
M. Andreoni,
G. Rezza, and B. Ensoli.
1999.
Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells.
J. Virol.
73:4029-4041[Abstract/Free Full Text].
|
| 40.
|
Monini, P.,
S. Colombini,
M. Stürzl,
D. Goletti,
A. Cafaro,
C. Sgadari,
S. Buttò,
M. Franco,
P. Leone,
S. Fais,
P. Leone,
G. Melucci-Vigo,
C. Chiozzini,
F. Carlini,
G. Ascherl,
E. Cornali,
C. Zietz,
E. Ramazzotti,
F. Ensoli,
M. Andreoni,
P. Pezzotti,
G. Rezza,
R. Yarchoan,
R. C. Gallo, and B. Ensoli.
1999.
Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma.
Blood
93:4044-4058[Abstract/Free Full Text].
|
| 41.
|
Moore, P. S.,
C. Boshoff,
R. A. Weiss, and Y. Chang.
1996.
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.
Science
274:1739-1744[Abstract/Free Full Text].
|
| 42.
|
Moore, P. S.,
L. A. Kingsley,
S. D. Holmberg,
T. Spira,
P. Gupta,
D. R. Hoover,
J. P. Parry,
L. J. Conley,
H. W. Jaffe, and Y. Chang.
1996.
Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma.
AIDS
10:175-180[Medline].
|
| 43.
|
Moosa, M. R.,
F. K. Treurnicht,
E. J. van Rensburg,
J. W. Schneider,
H. F. Jordaan, and S. Engelbrecht.
1998.
Detection and subtyping of human herpesvirus-8 in renal transplant patients before and after remission of Kaposi's sarcoma.
Transplantation
66:214-218[Medline].
|
| 44.
|
Neipel, F.,
J.-C. Albrecht,
A. Ensser,
Y.-Q. Huang,
J. J. Li,
A. E. Friedman-Kien, and B. Fleckenstein.
1997.
Human herpesvirus 8 encodes a homolog of interleukin-6.
J. Virol.
71:839-842[Abstract].
|
| 45.
|
Ohler, U.,
S. Harbeck,
H. Niemann,
E. Noth, and M. G. Reese.
1999.
Interpolated Markov chains for eukaryotic promoter recognition.
Bioinformatics
15:362-369[Abstract/Free Full Text].
|
| 46.
|
Oksenhendler, E.,
G. Carcelain,
Y. Aoki,
E. Boulanger,
A. Maillard,
J. P. Clauvel, and F. Agbalika.
2000.
High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman's disease in HIV-infected patients.
Blood
96:2069-2073[Abstract/Free Full Text].
|
| 47.
|
Orenstein, J. M.,
S. Alkan,
A. Blauvelt,
K. T. Jeang,
M. D. Weinstein,
D. Ganem, and B. Herndier.
1997.
Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy.
AIDS
11:F35-F45[CrossRef][Medline].
|
| 48.
|
Osman, M.,
T. Kubo,
J. Gill,
F. Neipel,
M. Becker,
G. Smith,
R. Weiss,
B. Gazzard,
C. Boshoff, and F. Gotch.
1999.
Identification of human herpesvirus 8-specific cytotoxic T-cell responses.
J. Virol.
73:6136-6140[Abstract/Free Full Text].
|
| 49.
|
Parravicini, C.,
B. Chandran,
M. Corbellino,
E. Berti,
M. Paulli,
P. S. Moore, and Y. Chang.
2000.
Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
Am. J. Pathol.
156:743-749[Abstract/Free Full Text].
|
| 50.
|
Parravicini, C.,
S. J. Olsen,
M. Capra,
F. Poli,
G. Sirchia,
S. J. Gao,
E. Berti,
A. Nocera,
E. Rossi,
G. Bestetti,
M. Pizzuto,
M. Galli,
M. Moroni,
P. S. Moore, and M. Corbellino.
1997.
Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients.
Blood
90:2826-2829[Abstract/Free Full Text].
|
| 51.
| Reese, M. G. Application of a time-delay
neural network to the annotation of the Drosophila
melanogaster genome. Comput. Chem., in press.
|
| 52.
|
Reese, M. G.,
F. H. Eeckman,
D. Kulp, and D. Haussler.
1997.
Improved splice site detection in Genie.
J. Comput. Biol.
4:311-323[Medline].
|
| 53.
|
Renne, R.,
W. Zhong,
B. Herndier,
M. McGrath,
N. Abbey,
D. Kedes, and D. Ganem.
1996.
Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.
Nat. Med.
2:342-346[CrossRef][Medline].
|
| 54.
|
Renwick, N.,
T. Halaby,
G. J. Weverling,
N. H. Dukers,
G. R. Simpson,
R. A. Coutinho,
J. M. Lange,
T. F. Schulz, and J. Goudsmit.
1998.
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
AIDS
12:2481-2488[CrossRef][Medline].
|
| 55.
|
Rezza, G.,
M. Andreoni,
M. Dorrucci,
P. Pezzotti,
P. Monini,
R. Zerboni,
B. Salassa,
V. Colangeli,
L. Sarmati,
E. Nicastri,
M. Barbanera,
R. Pristera,
F. Aiuti,
L. Ortona, and B. Ensoli.
1999.
Human herpesvirus-8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases.
J. Natl. Cancer Inst.
91:1468-1474[Abstract/Free Full Text].
|
| 56.
|
Roizman, B., and A. E. Sears.
1996.
Herpes simplex viruses and their replication, p. 2231-2241.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 57.
|
Russo, J. J.,
R. A. Bohenzky,
M. C. Chien,
J. Chen,
M. Yan,
D. Maddalena,
J. P. Parry,
D. Peruzzi,
I. S. Edelman,
Y. Chang, and P. S. Moore.
1996.
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV-8).
Proc. Natl. Acad. Sci. USA
93:14862-14867[Abstract/Free Full Text].
|
| 58.
|
Seaman, W. T.,
D. Ye,
R. X. Wang,
E. E. Hale,
M. Weisse, and E. B. Quinlivan.
1999.
Gene expression from the ORF50/K8 region of Kaposi's sarcoma-associated herpesvirus.
Virology
263:436-449[CrossRef][Medline].
|
| 59.
|
Sirianni, M. C.,
L. Vincenzi,
V. Fiorelli,
S. Topino,
E. Scala,
S. Uccini,
A. Angeloni,
A. Faggioni,
D. Cerimele,
F. Cottoni,
F. Aiuti, and B. Ensoli.
1998.
-Interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages.
Blood
91:968-976[Abstract/Free Full Text].
|
| 60.
|
Soulier, J.,
L. Grollet,
E. Oksenhendler,
P. Cacoub,
D. Cazals-Hatem,
P. Babinet,
M. F. d'Agay,
J. P. Clauvel,
M. Raphael, and L. Degos.
1995.
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.
Blood
86:1276-1280[Abstract/Free Full Text].
|
| 61.
|
Staskus, K. A.,
W. Zhong,
K. Gebhard,
B. Herndier,
H. Wang,
R. Renne,
J. Beneke,
J. Pudney,
D. J. Anderson,
D. Ganem, and A. T. Haase.
1997.
Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.
J. Virol.
71:715-719[Abstract].
|
| 62.
|
Stürzl, M.,
A. Wunderlich,
G. Ascherl,
C. Hohenadl,
P. Monini,
C. Zietz,
P. J. Browning,
F. Neipel,
P. Biberfeld, and B. Ensoli.
1999.
Human herpesvirus-8 (HHV-8) gene expression in Kaposi's sarcoma (KS) primary lesions: an in situ hybridization study.
Leukemia
13:110-112[CrossRef][Medline].
|
| 63.
|
Stürzl, M.,
C. Hohenadl,
C. Zietz,
E. Castanos-Velez,
A. Wunderlich,
G. Ascherl,
P. Biberfeld,
P. Monini,
P. J. Browning, and B. Ensoli.
1999.
Expression of the K13/vFLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells.
J. Natl. Cancer Inst.
91:1725-1733[Abstract/Free Full Text].
|
| 64.
|
Stürzl, M.,
C. Blasig,
A. Schreier,
F. Neipel,
C. Hohenadl,
E. Cornali,
G. Ascherl,
S. Esser,
N. H. Brockmeyer,
M. Ekman,
E. E. Kaaya,
E. Tschachler, and P. Biberfeld.
1997.
Expression of HHV-8 latency-associated T0.7 RNA in spindle cells and endothelial cells of AIDS-associated, classical and African Kaposi's sarcoma.
Int. J. Cancer
72:68-71[CrossRef][Medline].
|
| 65.
|
Stürzl, M.,
H. Brandstetter,
C. Zietz,
B. Eisenburg,
G. Raivich,
D. P. Gearing,
N. H. Brockmeyer, and P. H. Hofschneider.
1995.
Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi's sarcoma: a combined in vitro and in vivo analysis.
Oncogene
10:2007-2016[Medline].
|
| 66.
|
Stürzl, M.,
W. K. Roth,
N. H. Brockmeyer,
C. Zietz,
B. Speiser, and P. H. Hofschneider.
1992.
Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance.
Proc. Natl. Acad. Sci. USA
89:7046-7050[Abstract/Free Full Text].
|
| 67.
|
Sun, R.,
S.-F. Lin,
K. Staskus,
L. Gradoville,
E. Grogan,
A. Haase, and G. Miller.
1999.
Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression.
J. Virol.
73:2232-2242[Abstract/Free Full Text].
|
| 68.
|
Sun, R.,
S.-F. Lin,
L. Gradoville, and G. Miller.
1996.
Polyadenylylated nuclear RNA encoded by Kaposi sarcoma-associated herpesvirus.
Proc. Natl. Acad. Sci. USA
93:11883-11888[Abstract/Free Full Text].
|
| 69.
|
Sun, R.,
S.-F. Lin,
L. Gradoville,
Y. Yuan,
F. Zhu, and G. Miller.
1998.
A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus.
Proc. Natl. Acad. Sci. USA
95:10866-10871[Abstract/Free Full Text].
|
| 70.
|
Thome, M.,
P. Schneider,
K. Hofmann,
H. Fickenscher,
E. Meinl,
F. Neipel,
C. Mattmann,
K. Burns,
J. L. Bodmer,
M. Schroter,
C. Scaffidi,
P. H. Krammer,
M. E. Peter, and J. Tschopp.
1997.
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.
Nature
386:517-521[CrossRef][Medline].
|
| 71.
|
Whitby, D.,
M. R. Howard,
M. Tenant-Flowers,
N. S. Brink,
A. Copas,
C. Boshoff,
T. Hatzioannou,
F. E. Suggett,
D. M. Aldam,
A. S. Denton,
R. F. Miller,
I. V. D. Weller,
R. A. Weiss,
R. S. Tedder, and T. F. Schulz.
1995.
Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma.
Lancet
346:799-802[CrossRef][Medline].
|
| 72.
|
Whitley, R. J.
1996.
Herpes simplex viruses, p. 2297-2342.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 73.
|
Zhong, W.,
H. Wang,
B. Herndier, and D. Ganem.
1996.
Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma.
Proc. Natl. Acad. Sci. USA
93:6641-6646[Abstract/Free Full Text].
|
| 74.
|
Zhu, F. X.,
T. Cusano, and Y. Yuan.
1999.
Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus.
J. Virol.
73:5556-5567[Abstract/Free Full Text].
|
Journal of Virology, August 2001, p. 7161-7174, Vol. 75, No. 15
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.15.7161-7174.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Majerciak, V., Yamanegi, K., Zheng, Z.-M.
(2006). Gene Structure and Expression of Kaposi's Sarcoma-Associated Herpesvirus ORF56, ORF57, ORF58, and ORF59. J. Virol.
80: 11968-11981
[Abstract]
[Full Text]
-
Ribechini, E., Fortini, C., Marastoni, M., Traniello, S., Spisani, S., Monini, P., Gavioli, R.
(2006). Identification of CD8+ T Cell Epitopes within Lytic Antigens of Human Herpes Virus 8. J. Immunol.
176: 923-930
[Abstract]
[Full Text]
-
Taylor, J. L., Bennett, H. N., Snyder, B. A., Moore, P. S., Chang, Y.
(2005). Transcriptional Analysis of Latent and Inducible Kaposi's Sarcoma-Associated Herpesvirus Transcripts in the K4 to K7 Region. J. Virol.
79: 15099-15106
[Abstract]
[Full Text]
-
Coleman, H. M., Brierley, I., Stevenson, P. G.
(2003). An Internal Ribosome Entry Site Directs Translation of the Murine Gammaherpesvirus 68 MK3 Open Reading Frame. J. Virol.
77: 13093-13105
[Abstract]
[Full Text]
-
Dourmishev, L. A., Dourmishev, A. L., Palmeri, D., Schwartz, R. A., Lukac, D. M.
(2003). Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis. Microbiol. Mol. Biol. Rev.
67: 175-212
[Abstract]
[Full Text]
-
Ahn, J. W., Powell, K. L., Kellam, P., Alber, D. G.
(2002). Gammaherpesvirus Lytic Gene Expression as Characterized by DNA Array. J. Virol.
76: 6244-6256
[Abstract]
[Full Text]